Pharmos Corporation is a biopharmaceutical company that discovers and develops novel therapeutics to treat a range of diseases of the nervous system, including disorders of the brain-gut axis, with a focus on painlinflammation and autoimmune
disorders. The Company's lead product, dextofisopam, is being studied in a Phase 2b clinical trial in patients with irritable
bowel syndrome (16s). In a Phase 2a IBS study, dextofisopam demonstrated a statistically significant effect compared to
placebo on the primary efficacy endpoint of adequate relief (n=141, p=0.033) and was very well tolerated
Although not actively under development, the Company has solid expertise and proprietary know-how in the discovery and
TeXopment of synthetic cannabinoid compounds, especially CB2 receptor-selective (CB2-selective) agonists. PRS-639,058,
the leading CB2-selective agonist, has demonstrated promising preclinical data in neuropathic pain. Various other CB2-
selective compounds from Pharmos' library are in preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis,
inflammatory bowel disease qnd other disorders. These CB2 related assets are available for salellicensing. In February 2009
the Company entered into an agreement to sell certain of these CB2 assets
